Literature DB >> 22944627

HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

David M Phelan1, Gregory A Poland.   

Abstract

Humoral and cell-mediated immune responses are important in protection against measles. Non-response to vaccination has been associated with specific HLA-DR and HLA-DQ alleles; however, little is known about the relative importance of these alleles in the cellular immune response induced by measles virus vaccine. To investigate the role of HLA-DR/DQ class II restriction, a small pilot study was conducted. Lymphoproliferation assays using class II DR and DQ-specific monoclonal antibodies (MoAb) were performed at one week and two weeks post immunization with MMRII vaccine. The mean stimulation index (SI) was 4.4 and 5.3 at one and two weeks with reductions in SI of 47.6% and 70.2%, respectively, following the addition of DR-specific MoAb (p<0.001). These results clearly show that a significant proportion of the cell-mediated immune response to measles virus vaccine, as measured by SI, is HLA-DR restricted.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944627      PMCID: PMC3473139          DOI: 10.1016/j.vaccine.2012.08.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes.

Authors:  G A Poland
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

2.  Consistency of HLA associations between two independent measles vaccine cohorts: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-25       Impact factor: 3.641

3.  Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination.

Authors:  N Bautista-López; B J Ward; E Mills; D McCormick; N Martel; S Ratnam
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

4.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; R A Vierkant; S J Jacobsen; V S Pankratz; D J Schaid
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

5.  Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

Authors:  Inna G Ovsyannikova; Neelam Dhiman; Robert M Jacobson; Robert A Vierkant; Gregory A Poland
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

6.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; Stephen Naylor; David C Muddiman; Gregory A Poland
Journal:  Virology       Date:  2003-08-01       Impact factor: 3.616

8.  Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.

Authors:  A Jaye; A F Magnusen; A D Sadiq; T Corrah; H C Whittle
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

9.  Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals.

Authors:  Inna G Ovsyannikova; Gregory A Poland; Nathan J Easler; Robert A Vierkant
Journal:  Hum Immunol       Date:  2004-03       Impact factor: 2.850

10.  Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis.

Authors:  S Jacobson; M L Flerlage; H F McFarland
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.